Next-Generation Targeted Therapy in B-Cell Malignancies: Sonrotoclax + Zanubrutinib

Dr Shadman frames the clinical need for treatment mechanisms beyond conventional BTK inhibition in patients with relapsed or refractory B-cell malignancies.

Dr. Mazyar Shadman discusses the scientific rationale for combining sonrotoclax with zanubrutinib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Dr Shadman addresses tumor lysis syndrome, a longstanding concern with BCL2 inhibition, in light of the absence of any tumor lysis syndrome events in this study.